An editorial discusses the limitations of the data and suggests it would be hasty to conclude, based on this study’s negative findings for specific drug classes, that drugs in the class have no associations with autism because there may be other mechanisms at play. It adds that it is important to recognise that a full profile of the pharmacological properties of many of the drugs examined in this study is still unknown. It agrees with the researchers that the study is exploratory.